by: Colin Scibetta, MD (@colinscibetta)
Malignant bowel obstructions are a known complication of advanced cancer, especially in ovarian and gastrointestinal, and a frequent reason for admission to the hospital. Somatostatin analogues (such as octreotide) reduce gastric secretions and intestinal activity and there is some evidence for their use in improving symptoms of malignant bowel obstructions.
A randomized control trial published last year out of Australia sought to understand the benefit, if any, of adding IV octreotide to a standardized regimen of steroids and histamine blockers.
A little about the Study
This was a double blind, placebo controlled randomized trial of patients with nausea and vomiting from a confirmed malignant bowel obstruction. Patients were enrolled at multiple sites by providers from different specialties (ER, general medicine, oncology and palliative care) after the diagnosis was confirmed and assuming they did not meet criteria for immediate surgery or chemotherapy. Patients were randomized into Standard Therapy (placebo + IV dexamethasone, Ranitidine, IV hydration) or Octreotide groups (standard therapy + octreotide 600mcg infused over 24 hours). They included patients older than 18 years with advanced cancer, presenting with vomiting from malignant bowel obstruction between August 2008 and May 2012.
They excluded patients who had immediate indication for surgery or cancer directed therapy after consultation with the patient’s oncologist. Additional exclusion criteria included severe renal impairment, cirrhosis, existing venting G or J tube, a previous adverse reaction to any of the study drugs, and an Australian-modified Karnofsky performance score of less than 30.
The authors looked at a lot of different outcomes. The primary outcome was the number of days free of vomiting as reported by patients at 72 hours. They also looked at a host of secondary outcomes, including a patient-rated Global Impression of Change (GIC) scale, number of patient-reported episodes of vomiting per day, survival, nausea, brief pain inventory, functional status, PRN medication use (as dictated by the study protocol), and treatment failure. Treatment failure was defined as persistent vomiting, insertion of NG or venting G tube, or surgery.
The PRN medication protocol included hyoscine butylbromide (an anti-spasmodic medication) for colicky pain, opioids for non-colicky pain, and haloperidol or metoclopramide for nausea and vomiting.
Did Octreotide work for malignant bowel obstruction, as measured by the primary outcome?
No. There was no difference in mean number of days free of vomiting between the octreotide (1.87 days) and Standard Therapy group (1.69), with p-value of 0.47. In fact, patients in both groups demonstrated a significant drop in number of episodes of vomiting between day 0 and day 1.
There were also no differences detected in patients reported Global Impression of Change scores, presence or intensity of nausea, pain scores, or survival. Patients in the octreotide group were more likely to be administered hyoscine butylbromide for colicky abdominal pain (p=0.004). The study was not powered to detect differences in secondary outcomes.
Of note, the authors comment in the results section of the paper that after an adjusted multivariable regression analysis of secondary outcomes, they found a statistically significant reduction in the number of episodes of vomiting in patients treated with octreotide (RR=0.40, p=0.019). Interestingly, this was not mentioned in the discussion section and did not appear to influence the authors conclusions.
Key things to consider when interpreting this study
It is worth mentioning that the dose of octreotide used in this study was higher than that in previous studies (600 mcg/24 hours), and the authors do not address this. In addition, the standard regimen of IV ranitidine and dexamethasone used in both the control and treatment arms of the study is far from universal, and in fact varies widely across clinical practices. Importantly, patients in both arms of this trial reported marked improvements in symptoms and overall GIC score over the course of 3 days -- in particular between days 0 and 1. This change was statistically significant, and highlights that patients in both arms tended to improve, regardless of whether they received octreotide. Whether this reflects the natural history of malignant bowel obstructions in this population or the efficacy of the "standardized" medical therapies given to both groups is not clear.
Additionally, this study does not tell us about the potential benefit of octreotide therapy beyond a 72 hour window. Questions about the benefit of longer term dosing of octreotide in patients with recurrent or non-resolving malignant bowel obstructions are not addressed by this study.
What’s the take home point?
Ultimately, the results of this well designed and rigorously implemented randomized control trial do NOT support the use of IV octreotide in the acute management of malignant bowel obstruction. Not only did octreotide fail to demonstrate a reduction in vomiting over a 72 hour period (primary outcome), there was no meaningful difference in any of the secondary outcomes – such as pain, episodes of vomiting, or nausea.
The lack of demonstrated benefit is important because octreotide is a costly medication that requires either continuous, frequent subcutaneous or IV dosing, or long-acting depot formulations that may take several weeks to reach therapeutic levels. Furthermore, the observed increased use of anti-spasmodics in the treatment group raises the possibility that octreotide may even contribute to abdominal discomfort in these patients.
 Currow DC, Quinn S, Agar M, et al. Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. Journal of Pain and Symptom Management. 2014.09.013. [Epub ahead of print]